Unapproved gene therapy for boosting longevity is set to go on sale

A US company plans to sell an unapproved gene therapy overseas that aims to extend life by enhancing the production of the anti-aging protein klotho. This move sidesteps the FDA's regulatory process, raising ethical and safety concerns. While the therapy's potential to delay aging is enticing, its lack of approval means there's no guarantee of its efficacy or safety, highlighting the urgent need for stringent oversight in medical advancements. This situation underscores the ongoing debate about the balance between scientific innovation and regulatory caution.